Tobacco cessation within TB programmes: A ‘real world’ solution for countries with dual burden of disease was a Clinical Trial of an Investigational Medicinal Product (CTIMP). Its study design was double-blind, randomized, parallel group, placebo-controlled trial in which adults diagnosed with pulmonary TB (PTB) disease have been screened at 13 TB diagnostic and management centers in Federal Capital and two provinces e.g. Punjab and KPK of Pakistan. The primary objective of this study was to assess the effectiveness and cost-effectiveness of cytisine when added to behavioral support for tobacco cessation compared to behavioral support alone on tobacco cessation in TB patients who smoke tobacco on a daily basis. This trial is funded by the European Commission under the Research and Innovation action, H2020-HCO-2015 Funding scheme; Grant number 680995. Trial medications are supplied by Aflofarm Pharma Poland. The estimated trial recruitment period was 8 months and total period was about 26 months starting from June, 2017 to September, 2019.

Donor: European Commission under the Research and Innovation action, H2020-HCO-2015 Funding scheme
Fund Ref. No: 680995
Sponsor: University of York, UK
Local Partner: National Tuberculosis Control Program [NTP], Pakistan.